LIVE

AGGREGATED External reporting by Bloomberg. This page summarizes the publisher's feed entry; the full article is on www.bloomberg.com.

Boehringer, Sino Enter Cancer Drug Deal Worth Over $7 Billion

BLOOMBERG · Sonja Wind ·

Boehringer Ingelheim GmbH signed a licensing deal potentially worth more than $7 billion with China’s Sino Biopharmaceutical Limited and its subsidiaries for experimental cancer treatments.

READ THE ORIGINAL AT BLOOMBERG ↗ MORE FROM THIS SOURCE

RELATED REPORTING